Descripción del proyecto
Vacuna de nueva generación contra la enfermedad neumocócica
Solo en Europa, la enfermedad neumocócica es responsable de más de doscientas mil muertes cada año. Las vacunas disponibles son caras y los países en desarrollo no pueden permitirse brindar la protección necesaria a sus ciudadanos. 98 %Al mismo tiempo, la resistencia a antibióticos y la adaptación de «Streptococcus pneumoniae» reducen aún más la eficacia de las vacunas antineumocócicas. La empresa británica Immunobiology Ltd. ha desarrollado PnuBioVax™, una vacuna antineumocócica nueva y segura que protege contra todas las cepas neumocócicas. Durante el proyecto PnuBioVax, financiado con fondos europeos, se llevó a cabo un estudio de viabilidad de esta nueva vacuna, así como un análisis completo de su potencial técnico y comercial. Las características de PnuBioVax™, junto con su bajo coste de fabricación, pueden convertirla en la vacuna preferida en los países en desarrollo, lo que contribuirá a la lucha mundial contra la enfermedad neumocócica.
Objetivo
Pneumococcal disease, caused by the pathogenic bacteria Streptococcus pneumoniae, is a major cause of mortality in the young and elderly. In Europe, it is responsible for 230,000 annual deaths and an economic burden of € 10B annually. Due to the high cost of the current vaccines, rates of infant disease and death are even higher in developing countries, accounting for 1.6M deaths per year. The introduction of pneumococcal vaccines in Europe over the 20th century was pivotal in the reduction of pneumococcal pneumonia cases by 31%. Despite these good results, vaccine efficiency is now decreasing due to the adaptation of S. pneumoniae to the existing vaccines, but also due to its growing antibiotic resistance.
ImmunoBiology’s (ImmBio) platform technology has been used to create a pneumococcal vaccine called PnuBioVax™ (PBV) that aims to address the burden of the disease by offering protection against 100% of the pneumococcal strains. As a result of low manufacturing costs (<€ 1), PBV could become a game changer in the combat of the disease, facilitating its adoption in developing countries. The manufacturing cost of PBV represents a reduction of >95% compared to PCV13, the market leader, estimated at € 20. The vaccine has already been tested in humans, demonstrating its safety and effectiveness.
ImmBio is an innovative company, established in 1999 in the UK, which develops state-of-the-art vaccines using the ImmBioVax™ (IBV) vaccine platform technology. To date, ImmBio has raised circa € 10M in grants and awards. These funds, allowed the company to take the IBV technology from concept to clinical readiness products. The proposed work in Phase 1 of the SME instrument fits into their overall plan to reach the market by contributing to the financial resources needed to complete PBV’ clinical studies and ensure market uptake.
Ámbito científico
- medical and health sciencesclinical medicinepneumology
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
CB22 3AT CAMBRIDGE
Reino Unido
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.